The story
Founded by Emily Leproust in 2013.1
TWST on Nasdaq
Twist Bioscience
Logo: Gillian Jarvis, CC BY-SA 4.0, via Wikimedia Commons4
American Biotechnology company
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Krystal Biotech, Inc., Immunocore Holdings plc or Denali Therapeutics Inc., or pick any stock.
- TickerTWST on Nasdaq1
- Industrybiotechnology1
- HeadquartersSan Francisco1
- Websitewww.twistbioscience.com
- Legal formcorporation1
- Incorporated inDE6
- Business address681 Gateway Blvd., South San Francisco, Ca 940806
- Filer categoryLarge accelerated filer6
See how the biggest companies compare on our leaderboards
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-36.2%Operating margin5
-20.6%Net margin5
20.3%Revenue growth, 20255
-16.4%Return on equity5
-$75.6MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Ngs Tools brought in 55% of the revenue Twist Bioscience broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Ngs Tools | $123.7M | $169.1M | $208.1M |
| Synthetic Genes | $73.5M | $92.7M | $113.6M |
| Antibody Discovery | $23.2M | $20.3M | $23.5M |
| Oligo Pools | $14.5M | $16.9M | $20.2M |
| Dna And Biopharma Libraries | $10.2M | $13.9M | $11.2M |
Regions
Americas brought in 60% of the revenue Twist Bioscience broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Americas | $151.3M | $193.9M | $225.6M |
| EMEA | $71.4M | $92.6M | $124.2M |
| Asia Pacific | $22.5M | $26.5M | $26.8M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue36¢$185.6M
- Research and development16¢$80.3M
- Selling, general and admin48¢$247.0M
- Income tax0¢$719.0K
Out of $376.6M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Revenues | $376.6M | $313.0M | $245.1M |
| Cost of revenues | $185.6M | $179.6M | $155.4M |
| Research and development expenses | $80.3M | $90.9M | $106.9M |
| Selling, general and administrative expenses | $247.0M | $218.4M | $189.7M |
| Restructuring and other costs | $0 | $0 | $9.4M |
| Change in fair value of contingent considerations and holdbacks | $0 | $0 | -$5.9M |
| Impairment of long-lived assets | $0 | $44.9M | $6.8M |
| Total costs and expenses | $512.8M | $533.8M | $462.3M |
| Loss from operations | -$136.3M | -$220.8M | -$217.2M |
| Gain on sale of business | $48.8M | $0 | $0 |
| Interest income | $11.4M | $15.3M | $14.4M |
| Other income (expense), net | -$903.0K | -$2.7M | -$672.0K |
| Loss before income taxes | -$77.0M | -$208.2M | -$203.5M |
| Income tax expense | -$719.0K | -$560.0K | -$1.2M |
| Net loss attributable to common stockholders | -$77.7M | -$208.7M | -$204.6M |
| Change in unrealized gain (loss) on investments | -$50.0K | $203.0K | $1.5M |
| Foreign currency translation adjustment | -$55.0K | $31.0K | -$423.0K |
| Comprehensive loss | -$77.8M | -$208.5M | -$203.5M |
| Net loss per share attributable to common stockholdersbasic (in dollars per share) | -$1.30 | -$3.60 | -$3.60 |
| Net loss per share attributable to common stockholdersdiluted (in dollars per share) | -$1.30 | -$3.60 | -$3.60 |
| Weighted average shares used in computing net loss per share attributable to common stockholdersbasic (in shares) | 59.8M shares | 58.0M shares | 56.9M shares |
| Weighted average shares used in computing net loss per share attributable to common stockholdersdiluted (in shares) | 59.8M shares | 58.0M shares | 56.9M shares |
| Sublease income | $1.1M | $0 |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-09-30 | 2025-02-28 | 2024-09-30 |
|---|---|---|---|
| Cash and cash equivalents | $183.0M | $226.3M | |
| Short-term investments | $49.4M | $50.1M | |
| Inventories | $28.3M | $24.1M | |
| Total current assets | $333.0M | $346.8M | |
| Property and equipment, net | $102.3M | $102.5M | |
| Operating lease right-of-use assets | $49.4M | $58.8M | |
| Goodwill | $82.2M | $85.8M | |
| Intangible assets, net | $13.4M | $14.5M | |
| Restricted cash, non-current | $2.4M | $2.8M | |
| Other non-current assets | $4.9M | $1.6M | |
| Total assets | $641.9M | $614.3M | |
| Accounts payable | $11.1M | $1.6M | |
| Accrued expenses | $23.1M | $15.1M | |
| Accrued compensation | $31.3M | $33.6M | |
| Current portion of operating lease liability | $13.8M | $14.8M | |
| Other current liabilities | $12.1M | $5.8M | |
| Total current liabilities | $91.4M | $71.0M | |
| Operating lease liability, net of current portion | $61.8M | $70.2M | |
| Liability related to the sale of future revenue | $15.0M | $0 | |
| Other non-current liabilities | $747.0K | $407.0K | |
| Total liabilities | $168.9M | $141.6M | |
| Common stock, $0.00001 par value 200,000 and 100,000 shares authorized at September 30, 2025 and 2024, respectively; 60,631 and 58,877 shares issued and outstanding at September 30, 2025 and 2024, respectively | $0 | $0 | |
| Additional paid-in capital | $1.8B | $1.7B | |
| Accumulated other comprehensive loss | -$627.0K | -$522.0K | |
| Accumulated deficit | -$1.3B | -$1.2B | |
| Total stockholders equity | $473.0M | $472.7M | |
| Total liabilities and stockholders equity | $641.9M | $614.3M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 |
| Common stock, share authorized (in shares) | 200.0M shares | 200.0M shares | 100.0M shares |
| Common stock, share issued (in shares) | 60.6M shares | 58.9M shares | |
| Common stock, outstanding (in shares) | 60.6M shares | 58.9M shares | |
| Accounts receivable, net | $57.0M | $34.9M | |
| Prepaid expenses and other current assets | $15.2M | $11.4M | |
| Investment in equity securities | $54.3M | $1.5M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Net loss | -$77.7M | -$208.7M | -$204.6M |
| Depreciation and amortization expense | $24.9M | $31.4M | $29.3M |
| Impairment of long-lived assets | $0 | $44.9M | $6.8M |
| Non-cash lease expense, net of tenant improvement allowance | -$20.0K | $940.0K | $2.6M |
| Stock-based compensation expense | $64.5M | $50.9M | $30.3M |
| Change in fair value of contingent considerations and holdbacks | $0 | $0 | -$5.9M |
| Gain on sale of business | -$48.8M | $0 | $0 |
| Other non-cash adjustments | $2.2M | $994.0K | $120.0K |
| Inventories | -$4.2M | $8.0M | $7.2M |
| Other non-current assets | -$1.6M | $431.0K | $1.4M |
| Accounts payable | $9.3M | -$11.8M | -$2.5M |
| Accrued expenses | $5.8M | $4.4M | $2.6M |
| Accrued compensation | -$2.4M | $7.9M | -$1.1M |
| Other liabilities | $6.6M | -$2.3M | -$108.0K |
| Net cash used in operating activities | -$47.6M | -$64.1M | -$142.5M |
| Purchases of property and equipment | -$28.0M | -$5.1M | -$27.8M |
| Purchases of investments | -$49.4M | -$51.9M | -$76.3M |
| Proceeds from maturity of investments | $50.1M | $53.9M | $154.7M |
| Proceeds from sale of business | $2.5M | $0 | $0 |
| Net cash provided by (used in) investing activities | -$24.8M | -$3.1M | $50.6M |
| Proceeds from exercise of stock options | $9.3M | $7.1M | $1.4M |
| Proceeds from the issuance of liability related to sale of future revenue | $15.0M | $0 | $0 |
| Proceeds from issuance under employee stock purchase plan | $4.2M | $3.8M | $3.9M |
| Repurchases of common stock for income tax withholding | -$16.0K | -$4.0M | -$4.4M |
| Net cash provided by financing activities | $28.5M | $6.9M | $911.0K |
| Effect of exchange rates on cash, cash equivalents and restricted cash | $143.0K | $126.0K | -$27.0K |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -$43.7M | -$60.1M | -$91.0M |
| Income taxes paid, net of refunds | $683.0K | $344.0K | $420.0K |
| Property and equipment additions included in accrued expenses and accounts payable | $2.4M | $92.0K | $772.0K |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $0 | $0 | $6.7M |
| Issuance of common stock in connection with the business acquisition | $0 | $0 | $5.9M |
| Tenant improvement allowance capitalized in property and equipment | $0 | $2.7M | $0 |
| Equity securities received as consideration for sale of business | $53.9M | $0 | $0 |
| Promissory note receivable received as consideration for sale of business | $1.7M | $0 | $0 |
| Conversion of convertible notes | $0 | $0 | $3.7M |
| Accounts receivable, net | -$22.4M | $8.4M | -$4.3M |
| Prepaid expenses and other current assets | -$3.7M | $382.0K | -$4.2M |
Leadership
Who has led Twist Bioscience, and when. Pick a name to see everywhere that person has worked.
- FounderEmily Leproust1
Timeline
Recent filings
- Oct 13, 20264 PRIMARY DOCUMENT
- Oct 9, 2026144
- Oct 7, 20264 PRIMARY DOCUMENT
- Oct 5, 20264 PRIMARY DOCUMENT
- Oct 5, 20264 PRIMARY DOCUMENT
- Oct 5, 20264 PRIMARY DOCUMENT
- Oct 5, 20264 PRIMARY DOCUMENT
- Oct 5, 20264 PRIMARY DOCUMENT
- Oct 5, 20264 PRIMARY DOCUMENT
- Oct 5, 2026144
- Oct 2, 2026144
- Oct 2, 2026144
- Oct 2, 2026144
- Oct 2, 2026144
- Oct 2, 2026144
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.twistbioscience.com1
- X (Twitter)x.com/TwistBioscience1
- Facebookwww.facebook.com/TwistBioscience1
- Instagramwww.instagram.com/twist_bioscience1
- YouTubewww.youtube.com/channel/UCXlma642mHPdoJKJNAKZkYg1
- LinkedInwww.linkedin.com/company/twist-bioscience1
- WikipediaTwist Bioscience
- WikidataQ43303430
- SEC EDGARCIK 1581280
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataTwist Bioscience on Wikidata
- 2
- 3WikipediaTwist Bioscience on Wikipedia
- 4Wikimedia CommonsTwist Bioscience logo by Gillian Jarvis, CC BY-SA 4.0
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15